EcoR1 Capital LLC acquired a new stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX – Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 450,000 shares of the company’s stock, valued at approximately $20,763,000. Vaxcyte comprises about 0.9% of EcoR1 Capital LLC’s portfolio, making the stock its 18th biggest holding.
A number of other large investors have also recently added to or reduced their stakes in PCVX. Smartleaf Asset Management LLC boosted its stake in Vaxcyte by 156.2% during the 4th quarter. Smartleaf Asset Management LLC now owns 597 shares of the company’s stock valued at $27,000 after acquiring an additional 364 shares during the last quarter. Caitong International Asset Management Co. Ltd boosted its stake in Vaxcyte by 1,463.4% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 641 shares of the company’s stock valued at $30,000 after acquiring an additional 600 shares during the last quarter. EverSource Wealth Advisors LLC lifted its position in shares of Vaxcyte by 33.0% in the 4th quarter. EverSource Wealth Advisors LLC now owns 741 shares of the company’s stock worth $34,000 after buying an additional 184 shares during the last quarter. Allworth Financial LP lifted its position in shares of Vaxcyte by 148.9% in the 3rd quarter. Allworth Financial LP now owns 1,222 shares of the company’s stock worth $44,000 after buying an additional 731 shares during the last quarter. Finally, Aster Capital Management DIFC Ltd bought a new position in shares of Vaxcyte in the 3rd quarter worth about $45,000. 96.78% of the stock is currently owned by institutional investors.
Insider Activity
In other news, CAO Elvia Cowan sold 3,000 shares of Vaxcyte stock in a transaction that occurred on Tuesday, April 7th. The shares were sold at an average price of $60.00, for a total value of $180,000.00. Following the transaction, the chief accounting officer owned 28,975 shares of the company’s stock, valued at $1,738,500. The trade was a 9.38% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Jim Wassil sold 2,250 shares of Vaxcyte stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $49.52, for a total transaction of $111,420.00. Following the completion of the transaction, the chief operating officer directly owned 158,494 shares in the company, valued at $7,848,622.88. This represents a 1.40% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 7,500 shares of company stock worth $419,288. 3.30% of the stock is owned by corporate insiders.
Analyst Ratings Changes
Check Out Our Latest Analysis on Vaxcyte
Vaxcyte Trading Up 2.8%
Vaxcyte stock opened at $50.67 on Thursday. The stock has a market cap of $7.32 billion, a price-to-earnings ratio of -7.36 and a beta of 1.24. The company’s 50-day moving average price is $53.74 and its two-hundred day moving average price is $52.69. Vaxcyte, Inc. has a 52 week low of $29.08 and a 52 week high of $65.00.
Vaxcyte (NASDAQ:PCVX – Get Free Report) last released its earnings results on Wednesday, May 6th. The company reported ($2.30) EPS for the quarter, missing the consensus estimate of ($1.74) by ($0.56). During the same quarter in the previous year, the business earned ($1.04) EPS. Research analysts expect that Vaxcyte, Inc. will post -7.56 earnings per share for the current fiscal year.
Vaxcyte Profile
Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.
Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.
Featured Stories
- Five stocks we like better than Vaxcyte
- Cheap Thrills: Why These 3 Entertainment Stocks Are Soaring
- CoreWeave Insider Sales Look Big, But Should Investors Worry?
- Critical Metals: Sizing Up This Tiny Rare-Earth Stock Making Big Moves
- Meta and Cloud Computing: Real Potential, or a Shot in the Dark?
Want to see what other hedge funds are holding PCVX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vaxcyte, Inc. (NASDAQ:PCVX – Free Report).
Receive News & Ratings for Vaxcyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxcyte and related companies with MarketBeat.com's FREE daily email newsletter.
